UroMems has completed the implantation of the UroActive smart, automated AUS in a female patient to treat stress urinary incontinence. Credit: UroMems / PRNewswire.

UroMems has announced the first implantation of its smart, automated artificial urinary sphincter (AUS), UroActive, in a female patient as part of a clinical study.

UroActive, which is powered by a MyoElectroMechanical System (MEMS), is claimed to be the first smart active implant designed for the treatment of stress urinary incontinence (SUI).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company will utilise data from this trial for the design and implementation of the pivotal clinical study in the US and Europe.

Professor Emmanuel Chartier-Kastler, Dr Aurélien Beaugerie and Dr Christophe Vaessen conducted the robotic-assisted procedure for the female recipient at La Pitié-Salpêtrière University Hospital in Paris, France.

The National Agency for the Safety of Medicines and Health Products approved the first-in-female procedure.

See Also:

UroMems CEO and co-founder Hamid Lamraoui said: “This is a unique accomplishment for UroMems and SUI in women.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are addressing the observations by so many physicians that there is a vast unmet need for a better way to definitively treat this female population.”

The company has designed the UroActive implantable electronic AUS to treat sphincter insufficiency in both male and female patients with SUI.

In November last year, the company announced the first-in-human (male) UroActive implant.

Recently, the company secured the Safer Technologies Program designation from the US Food and Drug Administration for this implant.

SUI, also known as involuntary urinary leakage, is expected to affect around 90 million Europeans and 40 million Americans.

This condition arises when the pressure within the bladder surpasses that of the muscle (sphincter) surrounding the urethra.